Lexicon Pharmaceuticals, Inc. cash flow to debt ratio of -109.02% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lexicon Pharmaceuticals, Inc.'s free cash flow has increased -62.27% from $-179.81M last year to $-67.85M, signaling increasing performance

Lexicon Pharmaceuticals, Inc.'s debt to equity ratio is 0.34, which means that the company's assets are healthy financed, signaling financial stability.

Lexicon Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.74 last year to 0.34 today, signaling strengthened financials

Lexicon Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Lexicon Pharmaceuticals, Inc.'s interest coverage ratio is -6.50, which means that the company struggles to meet interest obligations, signaling financial risk.

Lexicon Pharmaceuticals, Inc.'s profit margin has increased (-77.14%) in the last year from -644.78% to -147.38%, signaling increasing performance

Lexicon Pharmaceuticals, Inc.'s short-term assets of $101.89M exceed its short-term liabilities of $20.87M

Lexicon Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lexicon Pharmaceuticals, Inc.'s return on equity of -40.40%, is lower than 15.00%, indicating bad performance

Lexicon Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lexicon Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Lexicon Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lexicon Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Lexicon Pharmaceuticals, Inc.'s yearly earnings has increased -74.88% since last year from $-200.40M to $-50.34M, signaling increasing performance

Lexicon Pharmaceuticals, Inc.'s yearly revenue has increased 60.24% since last year from $31.08M to $49.80M, signaling increasing performance

ROIC -23.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lexicon Pharmaceuticals, Inc.'s 3-year revenue CAGR of 610.25% is positive, indicating growing revenue over the past 3 years

Lexicon Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Lexicon Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Lexicon Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Lexicon Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lexicon Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lexicon Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lexicon Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Lexicon Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lexicon Pharmaceuticals, Inc. has a price-to-book ratio of 6.02x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Lexicon Pharmaceuticals, Inc. has a price-to-sales ratio of 25.32x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue